Kyoto University

Takeda Pharmaceutical Company Limited

Thyas Co. Ltd.

Akitsu Hotta

Shin Kaneko

Kyoko Masuda

Hiroshi Kawamoto

Atsutaka Minagawa

Naoko Fujimoto

Eriya Kenjo

Hiroshi Ichise

Yutaka Shimazu

Peter David Gee

Rumiko Ochiai

Yukimasa Makita

Kumiko Iwabuchi

Masataka Ifuku

Noriko Sasakawa

Hongmei Li

Provided is a method for inducing T cells for a cell-based immunotherapy, comprising the steps of:

Method for inducing t cells for cell-based immunotherapy from pluripotent stem cells

A virus-like particle encapsulating a target protein is provided. The virus-like particle contain a Gag protein, and the Gag protein forms a dimer with the target protein.

Virus-like particles and use thereof

The present invention provides a delivery technique for delivering a gene modification tool capable of providing a high gene modification efficiency in cells. The composition according to the present invention is a composition for inducing gene modification at a target gene locus in a cell, the composition containing 1) a compound represented by formula (I) or a salt thereof; 2) a structural lipid; and 3) a guide RNA or a DNA including a sequence encoding the guide RNA, and/or an RNA-guided nuclease or a nucleic acid including a sequence encoding the RNA-guided nuclease. In formula (I), n represents an integer of 2 to 5, R represents a linear Calkyl group, a linear Calkenyl group, or a linear Calkadienyl group, and wavy lines each independently represent a cis-type bond or a trans-type bond.

Composition for modifying target gene

A method of skipping a target exon of a gene of interest in a genome uses CRISPR-Cas and guide RNA. The guide RNA contains a spacer sequence such that the site of cleavage by the CRISPR-Cas is positioned within 80 bases from the splice donor site immediately before the target exon or the splice acceptor site immediately after the target exon.

Method for inducing exon skipping by genome editing

Growing community of inventors

Kyoto, Japan

Akitsu Hotta